Facioscapulohumeral muscular dystrophy 2
MONDO:0008031Any facioscapulohumeral muscular dystrophy in which the cause of the disease is a mutation in the SMCHD1 gene.
Also known as: SMCHD1 facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 2, facioscapulohumeral muscular dystrophy caused by mutation in SMCHD1, facioscapulohumeral muscular dystrophy type 2, fascioscapulohumeral muscular dystrophy 2, digenic, digenic dominant, FSHD2, Fshd2, digenic, facioscapulohumeral muscular dystrophy 2, digenic
46 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
FSHD drug trial halted midway: what happened?
Disease control TerminatedThis study tested a drug called losmapimod for people with a rare muscle-weakening disease called FSHD. The goal was to see if the drug could slow muscle loss and improve arm function over 48 weeks. About 260 adults with FSHD were randomly assigned to receive either losmapimod or…
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Scientists gather leftover surgical tissue to unlock secrets of bone disease
Knowledge-focused TerminatedThis study collected bone, cartilage, skin, and fat tissue from 50 patients undergoing surgery at Children's National Medical Center. The goal was to grow cells from these tissues in the lab and analyze them to better understand bone and connective tissue diseases. The study was …
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC